Leerink Partnrs Has Negative Outlook of Moderna Q3 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for shares of Moderna in a report issued on Monday, August 4th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($2.33) per share for the quarter, down from their previous estimate of ($1.90). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. Leerink Partnrs also issued estimates for Moderna’s Q4 2025 earnings at ($3.12) EPS, FY2025 earnings at ($10.10) EPS, FY2026 earnings at ($7.72) EPS, FY2027 earnings at ($4.95) EPS and FY2028 earnings at ($3.50) EPS.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%. Moderna’s revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.33) EPS.

MRNA has been the topic of several other research reports. Evercore ISI set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Barclays decreased their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday. Bank of America reduced their target price on Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a report on Tuesday, July 22nd. UBS Group reduced their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup started coverage on Moderna in a research note on Friday, August 1st. They issued a “neutral” rating and a $40.00 target price for the company. Four investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $45.61.

Moderna Trading Down 2.8%

MRNA stock opened at $26.71 on Wednesday. The firm has a market cap of $10.39 billion, a P/E ratio of -3.55 and a beta of 1.83. Moderna has a 1-year low of $23.15 and a 1-year high of $91.99. The business’s 50 day moving average is $29.28 and its 200-day moving average is $30.15.

Institutional Trading of Moderna

Hedge funds have recently bought and sold shares of the stock. S Bank Fund Management Ltd bought a new stake in Moderna during the 1st quarter worth about $25,000. TD Private Client Wealth LLC increased its position in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after acquiring an additional 743 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in Moderna during the second quarter worth about $26,000. SVB Wealth LLC acquired a new position in Moderna during the first quarter valued at approximately $28,000. Finally, Whittier Trust Co. acquired a new position in Moderna during the second quarter valued at approximately $28,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.